Your browser is no longer supported. Please, upgrade your browser.
MREO Mereo BioPharma Group plc weekly Stock Chart
MREO [NASD]
Mereo BioPharma Group plc
Index- P/E- EPS (ttm)- Insider Own1.06% Shs Outstand67.74M Perf Week-8.06%
Market Cap193.07M Forward P/E- EPS next Y-0.19 Insider Trans0.00% Shs Float22.02M Perf Month-12.31%
Income- PEG- EPS next Q-0.26 Inst Own15.33% Short Float2.03% Perf Quarter147.83%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.39 Perf Half Y69.44%
Book/sh- P/B- EPS next Y59.60% ROA- Target Price- Perf Year4.01%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.69 - 4.27 Perf YTD-13.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.24% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low313.04% ATR0.28
Employees50 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)49.61 Volatility10.13% 8.17%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.16 Prev Close2.72
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume322.92K Price2.85
Recom1.00 SMA20-5.17% SMA507.41% SMA20037.74% Volume53,967 Change4.78%
Jun-30-20 07:00AM  
Jun-16-20 07:00AM  
Jun-04-20 07:00AM  
Mar-27-20 08:00AM  
Feb-28-20 07:00AM  
Feb-19-20 07:21AM  
03:00AM  
Feb-12-20 08:00AM  
Feb-11-20 07:23AM  
Feb-10-20 07:00AM  
Jan-14-20 07:00AM  
Jan-13-20 07:00AM  
Nov-11-19 06:30AM  
Oct-09-19 08:18AM  
Oct-07-19 08:00AM  
Sep-17-19 07:00AM  
Sep-10-19 08:00AM  
Sep-04-19 08:00AM  
Jul-16-19 08:00AM  
Jul-15-19 08:00AM  
Jun-14-19 08:47AM  
Jun-13-19 08:00AM  
May-30-19 07:33AM  
02:00AM  
May-03-19 12:09PM  
Apr-29-19 02:00AM  
Apr-26-19 08:00AM  
Apr-24-19 09:30AM  
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.